Piper Sandler Maintains Neutral on Inari Medical, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Adam Maeder has maintained a Neutral rating on Inari Medical (NASDAQ:NARI) with a price target of $50.
August 26, 2024 | 3:47 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler has reiterated a Neutral rating for Inari Medical with a $50 price target, indicating no expected significant short-term price movement.
The Neutral rating and maintained price target suggest that the analyst does not foresee significant changes in Inari Medical's stock price in the short term. This indicates stability rather than a bullish or bearish outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100